Breast cancer survivorship care widens past tamoxifen and aromatase inhibitor side-effect management
Vasomotor symptom therapy in breast cancer survivors, bone-health management with aromatase inhibitors, and structured survivorship programs are reshaping breast cancer survivorship care.
Breast cancer survivorship care has been an oncology-follow-up category with limited specific intervention for the consequences of long-term endocrine therapy. Non-hormonal vasomotor therapy now reaches breast cancer survivors who cannot use systemic hormone therapy. Bone-health management with aromatase inhibitors (denosumab, bisphosphonates, romosozumab in selected populations) is increasingly structured. Sexual health, cognitive function, and cardiovascular surveillance are formalising as survivorship-care components.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.